نتایج جستجو برای: telaprevir
تعداد نتایج: 686 فیلتر نتایج به سال:
The treatment of chronic hepatitis C virus (HCV) genotype 1 infection has been revolutionized by the introduction of direct-acting antiviral (DAA) agents (boceprevir and telaprevir) in combination with peginterferon and ribavirin. Although improved antiviral efficacy and shorter durations of therapy are anticipated, there are also potentially severe drug-drug interactions involving protease inh...
BACKGROUND Although the recommended treatment of hepatitis C continues to evolve as newer and more effective medications are made available, hepatitis C drug regimens consisting of a 3-drug combination of a protease inhibitor, pegylated interferon, and ribavirin were recommended by the American Association for the Study of Liver Diseases for the HCV genotype I beginning in 2011. Although more e...
Hepatitis C virus (HCV) infection represents a major health problem worldwide. Approximately 350,000 people die every year from hepatitis C related diseases. Antiviral therapy is given to prevent such complications. Advances in serological and molecular assays greatly improved the diagnosis of hepatitis C virus infection and the management of chronically infected patients. Sensitive real-time P...
The recent publication of two controlled trials on boceprevir and three on telaprevir heralds a new era for hepatitis C therapy 1-6 . Bocreprevir and telaprevir are protease inhibitors which act directly on the hepatitis C virus to inhibit replication and are referred to as direct acting antiviral agents (DAAâs). They are the first 2 such agents to be licensed but it is hoped that many more w...
Use of direct-acting antivirals sometimes causes viral drug resistance, resulting in inefficiency in treated patients in real-world practice. Therefore, how to rapidly and accurately evaluate drug resistance is an urgent problem to be solved for rational use and development of antivirals in the future. Here, we aim to develop a new method by which we can evaluate easily but effectively whether ...
A small-animal model for hepatitis C virus (HCV) infection was developed using severe combined immunodeficiency (SCID) mice encoding homozygous urokinase-type plasminogen activator (uPA) transplanted with human hepatocytes. Currently, limited information is available concerning the HCV clearance rate in the SCID mouse model and the virion production rate in engrafted hepatocytes. In this study,...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید